<code id='A25DCC91FB'></code><style id='A25DCC91FB'></style>
    • <acronym id='A25DCC91FB'></acronym>
      <center id='A25DCC91FB'><center id='A25DCC91FB'><tfoot id='A25DCC91FB'></tfoot></center><abbr id='A25DCC91FB'><dir id='A25DCC91FB'><tfoot id='A25DCC91FB'></tfoot><noframes id='A25DCC91FB'>

    • <optgroup id='A25DCC91FB'><strike id='A25DCC91FB'><sup id='A25DCC91FB'></sup></strike><code id='A25DCC91FB'></code></optgroup>
        1. <b id='A25DCC91FB'><label id='A25DCC91FB'><select id='A25DCC91FB'><dt id='A25DCC91FB'><span id='A25DCC91FB'></span></dt></select></label></b><u id='A25DCC91FB'></u>
          <i id='A25DCC91FB'><strike id='A25DCC91FB'><tt id='A25DCC91FB'><pre id='A25DCC91FB'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:explore    Page View:9
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In